News & Updates
June 15th 2022: Significant grant awardedThe Israeli Innovation Authority awarded the company, through a highly competitive and objective process, a 1 year grant of $500K for transitioning the company from R&D into Manufacturing.

Voyager Medical Research

Confidence in abdominal wall closure

Everything we do is intended to reduce severe post-surgical complications and help save lives.
We do so by developing unique, proprietary polymers that are designed specifically to help prevent complications.
Our first product, Voyager Surgical Suture, addresses the post-surgical complication of Incisional Hernia that is affecting up to 20% of patients undergoing a Laparotomy, leading to 3.4% mortality.
Our team is highly experienced and recognized in the field of wound-closure and biocompatible polymers.

The problem

Incisional Hernia

In a time frame of 5 years, 1 of every 5 patients will develop a Post-Operative Ventral Hernia (POVH) after an abdominal surgery (Open or Laparoscopic).

POVH is the protrusion of internal organs through the incision of a previous surgery, it is a serious complication that is difficult to repair with even higher incidence of recurrence after a primary repair.

In addition many patients with POVH suffer acute pain, physical and psychological distress, high morbidity and high mortality (3.5%).

One of the main reasons for POVH has to do with the surgical sutures used for abdominal wall closure. Gold standard absorbable sutures such as PDS-IIĀ® (Ethicon) offer a maximum tensile strength of 8 weeks, meaning that after 8 weeks the tissue is supposed to be self-supporting. Unfortunately 80% of patients are Immuno-suppressed, meaning that they have severe delays in wound-healing. Research shows that these patients require significantly more support time (around 16 weeks) for their abdominal wall before it could be considered self-supporting.

A surgical suture with extended tensile strength support will allow the tissue enough time to become self-sufficient and as a result reduce the incidence of POVH.

Voyager Surgical Suture

Our Solution

Voyager Surgical Suture (VSS) VSS is a monofilament, absorbable surgical suture, intended for abdominal wall closure.

The product is based on a co-polymer that was designed and validated in over 6 years of research at the Institute of Chemistry of the Hebrew University. VSS is composed of PPCA which is a unique co-polymer comprising Poly(Propylene Oxide) and Poly(Caprolactone) blocks, being chained extended with a diisocyanate (Hexamatheylene diisocyanate).

Unlike competitor products that only provide 8 weeks of abdominal wall support, VSS offers as much as 5-6 months of support, enough to allow healing even for the most immune-suppressed patient.

Our In-Vivo study show that when VSS is compared to the gold standard suture PDS-II, VSS is 74% stronger at 8 weeks and while PDS-II is no longer effective after 8 weeks VSS continues to show high and stable tensile strength at week 16.

Just over a year post-implantation VSS dissolves and is evacuated from the body safely.

Voyager surgical suture provides effective tissue support of 5-6 months which will reduce incisional hernia by at least 50%.

Better Knotability

An additional benefit of Voyager surgical suture is its improved knotability. When making a surgical knot, instead of 4 double knots required with all monofilament sutures such as PDS-II, VSS only requires 1 double knot. This leads to a much quicker closure without jeopardizing patient safety. Fewer ties may also lead to less inflammation and skin irritation.

In the picture: Violet suture (PDS II), Clear suture (Voyager Surgical Suture)

62.6m Laparotomies per year, an opportunity worth over $1b.

Nice To Meet You

Our Team

Ohad Lavi
Ohad Lavi
CEO, Founder
Ohad has over 20 years of experience in sales, marketing and Manufacturing of surgical devices and sutures in particular. Started as a sales rep for J&J selling sutures, now CEO for WCS Healthcare.
Prof. Daniel Cohn
Prof. Daniel Cohn
Chief Chemistry Scientist, Founder
A world-wide expert in the field of Bio-absorbable polymers, Medical Devices, Tissue engineering and Drug Delivery Systems. He is the Head of the Biomedical Polymers Laboratory at the Hebrew University of Jerusalem.
Prof. Ariel Halevi
Prof. Ariel Halevi
Chief Medical Scientist
A highly revered and experienced General surgeon. Retired as Chief of the surgical division at Assaf-Harofeh public hospital.

"There is always a way to do it better, Find it."

Thomas A. Edison

Find out today, how you can become an investor in Voyager Medical research